PMN ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. (PMN) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $1.60 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.8% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences Inc. is a development stage biotechnology company. It focused on discovering and developing medicine therapeutics to treat neurodegenerative diseases in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company's product portfolio includes PMN310, PMN350, PMN330, PMN110, PMN120 and PMN130 which are in its pre-clinical stage. ProMIS Neurosciences Inc.is headquartered in Toronto, Canada.
Sector
Healthcare
Industry
Biotechnology